New Therapies for Primary Biliary Cirrhosis

Annarosa Floreani, Irene Franceschet, Lisa Perini, Nora Cazzagon, M. Eric Gershwin, Christopher Bowlus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U.S. Food and Drug Administration. Patients with a biochemical response to UDCA therapy have a similar survival rate compared to the general population. However, up to 40 % of PBC patients do not achieve a complete response to UDCA, have an increased risk of liver-related death and liver transplantation, and represent a persistent medical need for new therapies. Several novel drugs have recently been studied and show potential efficacy in PBC. Obeticholic acid, a farnesoid X receptor agonist, has been tested in phase II trials and initial results after 1 year in a phase III international trial suggest that it may be effective in achieving a biochemical response in approximately 40 % of patients who do not completely respond to UDCA. Several small studies on fibrates have suggested that they may have efficacy, but larger studies are needed. Surprisingly, results of immunomodulators and biologics have not yet been able to demonstrate efficacy, but new approaches have shown promise in animal models and their translation to human clinical trials are awaited.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume48
Issue number2-3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Fibric Acids
Immunologic Factors
United States Food and Drug Administration
Therapeutics
Biological Products
Liver Transplantation
Liver Diseases
Survival Rate
Animal Models
Clinical Trials
Liver
Pharmaceutical Preparations
Population

Keywords

  • Anti-TNF-α
  • Budesonide
  • CXCL10 monoclonal antibody
  • Fibrates
  • Obeticholic acid
  • Primary biliary cirrhosis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

New Therapies for Primary Biliary Cirrhosis. / Floreani, Annarosa; Franceschet, Irene; Perini, Lisa; Cazzagon, Nora; Gershwin, M. Eric; Bowlus, Christopher.

In: Clinical Reviews in Allergy and Immunology, Vol. 48, No. 2-3, 01.06.2015, p. 263-272.

Research output: Contribution to journalArticle

Floreani, Annarosa ; Franceschet, Irene ; Perini, Lisa ; Cazzagon, Nora ; Gershwin, M. Eric ; Bowlus, Christopher. / New Therapies for Primary Biliary Cirrhosis. In: Clinical Reviews in Allergy and Immunology. 2015 ; Vol. 48, No. 2-3. pp. 263-272.
@article{8d47c748ed40415d8065caf007b90e4e,
title = "New Therapies for Primary Biliary Cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U.S. Food and Drug Administration. Patients with a biochemical response to UDCA therapy have a similar survival rate compared to the general population. However, up to 40 {\%} of PBC patients do not achieve a complete response to UDCA, have an increased risk of liver-related death and liver transplantation, and represent a persistent medical need for new therapies. Several novel drugs have recently been studied and show potential efficacy in PBC. Obeticholic acid, a farnesoid X receptor agonist, has been tested in phase II trials and initial results after 1 year in a phase III international trial suggest that it may be effective in achieving a biochemical response in approximately 40 {\%} of patients who do not completely respond to UDCA. Several small studies on fibrates have suggested that they may have efficacy, but larger studies are needed. Surprisingly, results of immunomodulators and biologics have not yet been able to demonstrate efficacy, but new approaches have shown promise in animal models and their translation to human clinical trials are awaited.",
keywords = "Anti-TNF-α, Budesonide, CXCL10 monoclonal antibody, Fibrates, Obeticholic acid, Primary biliary cirrhosis, Ursodeoxycholic acid",
author = "Annarosa Floreani and Irene Franceschet and Lisa Perini and Nora Cazzagon and Gershwin, {M. Eric} and Christopher Bowlus",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s12016-014-8456-5",
language = "English (US)",
volume = "48",
pages = "263--272",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - New Therapies for Primary Biliary Cirrhosis

AU - Floreani, Annarosa

AU - Franceschet, Irene

AU - Perini, Lisa

AU - Cazzagon, Nora

AU - Gershwin, M. Eric

AU - Bowlus, Christopher

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U.S. Food and Drug Administration. Patients with a biochemical response to UDCA therapy have a similar survival rate compared to the general population. However, up to 40 % of PBC patients do not achieve a complete response to UDCA, have an increased risk of liver-related death and liver transplantation, and represent a persistent medical need for new therapies. Several novel drugs have recently been studied and show potential efficacy in PBC. Obeticholic acid, a farnesoid X receptor agonist, has been tested in phase II trials and initial results after 1 year in a phase III international trial suggest that it may be effective in achieving a biochemical response in approximately 40 % of patients who do not completely respond to UDCA. Several small studies on fibrates have suggested that they may have efficacy, but larger studies are needed. Surprisingly, results of immunomodulators and biologics have not yet been able to demonstrate efficacy, but new approaches have shown promise in animal models and their translation to human clinical trials are awaited.

AB - Primary biliary cirrhosis (PBC) is a rare inflammatory liver disease for which ursodeoxycholic acid (UDCA) is the only therapy approved by the U.S. Food and Drug Administration. Patients with a biochemical response to UDCA therapy have a similar survival rate compared to the general population. However, up to 40 % of PBC patients do not achieve a complete response to UDCA, have an increased risk of liver-related death and liver transplantation, and represent a persistent medical need for new therapies. Several novel drugs have recently been studied and show potential efficacy in PBC. Obeticholic acid, a farnesoid X receptor agonist, has been tested in phase II trials and initial results after 1 year in a phase III international trial suggest that it may be effective in achieving a biochemical response in approximately 40 % of patients who do not completely respond to UDCA. Several small studies on fibrates have suggested that they may have efficacy, but larger studies are needed. Surprisingly, results of immunomodulators and biologics have not yet been able to demonstrate efficacy, but new approaches have shown promise in animal models and their translation to human clinical trials are awaited.

KW - Anti-TNF-α

KW - Budesonide

KW - CXCL10 monoclonal antibody

KW - Fibrates

KW - Obeticholic acid

KW - Primary biliary cirrhosis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84939988292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939988292&partnerID=8YFLogxK

U2 - 10.1007/s12016-014-8456-5

DO - 10.1007/s12016-014-8456-5

M3 - Article

C2 - 25331740

AN - SCOPUS:84939988292

VL - 48

SP - 263

EP - 272

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 2-3

ER -